Gonorrhea Treatment Guidelines

Primary Treatment Recommendation

• The Centers for Disease Control and Prevention recommends ceftriaxone 250 mg IM in a single dose PLUS azithromycin 1 g orally in a single dose for uncomplicated gonococcal infections of the cervix, urethra, rectum, and pharynx 1, 2
• Azithromycin is preferred over doxycycline due to convenience and compliance advantages of single-dose therapy, and substantially higher prevalence of gonococcal resistance to tetracycline than to azithromycin 1

Alternative Regimens

• If ceftriaxone is not available, the Centers for Disease Control and Prevention recommends cefixime 400 mg orally in a single dose PLUS azithromycin 1 g orally in a single dose, with a test-of-cure performed 1 week after treatment 3
• For patients with severe cephalosporin allergy, azithromycin 2 g orally in a single dose is recommended, with a test-of-cure performed 1 week after treatment 3

Rationale for Dual Therapy

• The Centers for Disease Control and Prevention recommends dual therapy due to rising antibiotic resistance patterns, which necessitate combination therapy to improve treatment efficacy and potentially delay emergence and spread of resistance to cephalosporins 1
• Dual therapy also addresses possible chlamydial co-infection 2

Special Considerations

• Pregnant women should not be treated with quinolones or tetracyclines, and the recommended treatment is a cephalosporin (ceftriaxone preferred), according to the Centers for Disease Control and Prevention 4
• For treatment failure, culture relevant clinical specimens, perform antimicrobial susceptibility testing, and consult an infectious disease specialist, as recommended by the Centers for Disease Control and Prevention 2, 3

Partner Management

• All sex partners from the preceding 60 days should be evaluated and treated, according to the Centers for Disease Control and Prevention 2, 3
• Patients should avoid sexual intercourse until therapy is completed and both they and their partners are asymptomatic, as recommended by the Centers for Disease Control and Prevention 4

Important Clinical Considerations

• Pharyngeal gonorrhea is more difficult to eradicate than urogenital or anorectal infections, according to the Centers for Disease Control and Prevention 4
• Azithromycin 1 g alone is insufficient for gonorrhea treatment, as recommended by the Centers for Disease Control and Prevention 4

Gonorrhea Treatment Recommendations

Antimicrobial Resistance Considerations

• Rising cefixime MICs have resulted in declining effectiveness for urogenital gonorrhea treatment, according to the Centers for Disease Control and Prevention 5
• Dual therapy with two antimicrobials with different mechanisms of action is recommended to improve treatment efficacy and potentially delay emergence of cephalosporin resistance, as suggested by the Centers for Disease Control and Prevention 5
• Quinolones (ciprofloxacin) are no longer recommended due to widespread resistance, as reported by the Centers for Disease Control and Prevention 6, 5

Site-Specific Considerations

• Pharyngeal gonorrhea is more difficult to eradicate than urogenital or anorectal infections, according to the Centers for Disease Control and Prevention 6
• Ceftriaxone has superior efficacy for pharyngeal infections compared to alternative treatments, as reported by the Centers for Disease Control and Prevention 5

Special Populations

• Ceftriaxone is the only recommended treatment for Men who have Sex with Men (MSM) due to higher prevalence of resistant strains, as recommended by the Centers for Disease Control and Prevention 6, 5
• Quinolones should not be used for infections in MSM, according to the Centers for Disease Control and Prevention 6
• Ceftriaxone is the only recommended treatment for patients with history of recent foreign travel, as suggested by the Centers for Disease Control and Prevention 6

Partner Management

• If partners' treatment cannot be ensured, expedited partner therapy may be considered, as recommended by the Centers for Disease Control and Prevention 6

Follow-Up Recommendations

• Patients with persistent symptoms after treatment should be evaluated by culture for N. gonorrhoeae, and any isolates should be tested for antimicrobial susceptibility, as recommended by the Centers for Disease Control and Prevention 6
• Consider retesting all patients 3 months after treatment due to high risk of reinfection, as suggested by the Centers for Disease Control and Prevention 6

Empiric Treatment for Gonorrhea and Chlamydia

Alternative Regimens

• For patients with severe cephalosporin allergy, the Centers for Disease Control and Prevention recommends spectinomycin 2 g IM in a single dose, which has poor efficacy (only 52%) against pharyngeal gonorrhea 7
• Patients with uncomplicated gonorrhea treated with recommended regimens do not need a test of cure, as stated by the Centers for Disease Control and Prevention 7

Important Clinical Considerations

• Azithromycin 1 g alone is insufficient for gonorrhea treatment, with only 93% efficacy, according to the Centers for Disease Control and Prevention 8

Empiric Treatment for Chlamydia and Gonorrhea

Rationale for Dual Therapy

• Co-infection is extremely common, with up to 40-50% of patients with gonorrhea also having chlamydia, making presumptive treatment for both organisms essential when empiric therapy is indicated, as recommended by the Centers for Disease Control and Prevention (CDC) 9, 10

Critical Pitfalls to Avoid

• Never use quinolones for gonorrhea treatment due to widespread resistance, as advised by the CDC 9, 10
• Ceftriaxone has superior efficacy for pharyngeal infections compared to oral alternatives, and is strongly preferred over cefixime for pharyngeal infections, as recommended by the CDC 9, 10

Gonorrhea Treatment Guidelines

Rationale for Current Regimen

• The Centers for Disease Control and Prevention (CDC) recommends that patients with severe cephalosporin allergy use azithromycin 2 g orally once, with mandatory test-of-cure at 1 week, although this regimen has lower efficacy and higher gastrointestinal side effects 11
• Pharyngeal gonorrhea is significantly more difficult to eradicate than urogenital or anorectal infections, and ceftriaxone 500 mg IM is the only reliably effective treatment for pharyngeal infections 11
• Never use fluoroquinolones (ciprofloxacin, ofloxacin) for gonorrhea treatment due to widespread resistance, despite their historical effectiveness (99.8% cure rate in 1998) 11
• Never use azithromycin 1 g alone due to insufficient efficacy (only 93% cure rate) 11
• Patients treated with recommended regimens do not need routine test-of-cure unless symptoms persist, but mandatory test-of-cure at 1 week is required for patients receiving cefixime or azithromycin monotherapy 11
• Patients with persistent symptoms should have culture with antimicrobial susceptibility testing 11

Treatment for Gonorrhoea

Site-Specific Considerations

• Most cases of ceftriaxone treatment failure involve the pharynx, not urogenital sites, and both spectinomycin and gentamicin have poor efficacy in the pharynx, with one study showing only 2 of 10 individuals with pharyngeal gonorrhoea treated with gentamicin were cured 12

Treatment Failure Management

• If treatment failure occurs, obtain specimens for culture and antimicrobial susceptibility testing immediately, and report the case to local public health officials within 24 hours, and consult an infectious disease specialist 12
• For suspected ceftriaxone treatment failure, recommended regimens include gentamicin 240 mg intramuscularly PLUS azithromycin 2 g orally (single dose), spectinomycin 2 g intramuscularly PLUS azithromycin 2 g orally, and ertapenem 1 g intramuscularly for 3 days 12

Gonorrhea Treatment Guidelines

Primary Treatment Regimen

• The Centers for Disease Control and Prevention (CDC) recommends cefixime 400 mg orally single dose PLUS azithromycin 1 g orally single dose as an alternative regimen when ceftriaxone is unavailable 13
• Mandatory test-of-cure at 1 week is required with the cefixime and azithromycin regimen 13

Alternative Regimens

• For patients with severe cephalosporin allergy, azithromycin 2 g orally single dose is an option, but has lower efficacy (only 93%) and high gastrointestinal side effects 13
• Gentamicin 240 mg IM single dose PLUS azithromycin 2 g orally single dose is an alternative regimen with a 100% cure rate in clinical trials 14

Critical Site-Specific Considerations

• Spectinomycin has only 52% efficacy for pharyngeal infections and should be avoided 13, 15
• Gentamicin also has poor pharyngeal efficacy (only 20% cure rate in one study) 14

Partner Management

• The CDC recommends evaluating and treating all sexual partners from the preceding 60 days 13
• Partners should receive the same dual therapy regimen for both gonorrhea and chlamydia 13

Treatment Failure Management

• If treatment failure is suspected, obtain specimens for culture and antimicrobial susceptibility testing immediately 14
• Report the case to local public health officials within 24 hours 13, 14
• Consult an infectious disease specialist 13, 14
• Recommended salvage regimens include gentamicin 240 mg IM PLUS azithromycin 2 g orally or ertapenem 1 g IM for 3 days 14

Special Populations

• In pregnancy, use ceftriaxone (preferred cephalosporin) PLUS azithromycin 1 g orally 15
• Never use quinolones or tetracyclines in pregnancy 15
• For men who have sex with men (MSM), do not use patient-delivered partner therapy due to high risk of undiagnosed coexisting STDs or HIV 13

Ceftriaxone 500mg IM + Azithromycin 1g: Treatment Assessment

Efficacy and Safety

• Ceftriaxone achieves a 99.1% cure rate for uncomplicated urogenital and anorectal gonorrhea, as recommended by the CDC 16
• Azithromycin 1g provides single-dose chlamydia coverage, eliminating the need for 7-day doxycycline in compliant patients, although the CDC recommends against using azithromycin 1g alone for gonorrhea due to its 93% efficacy 16
• The use of quinolones (ciprofloxacin, ofloxacin) is no longer recommended due to widespread resistance, despite their historical 99.8% cure rates, as stated in the MMWR Recommendations and Reports 16

Treatment Guidelines

• The CDC recommends ceftriaxone 500mg IM plus azithromycin 1g orally as the optimal single-dose dual therapy regimen for uncomplicated gonorrhea with presumptive chlamydia coverage 16
• This regimen is effective in treating gonorrhea at cervical, urethral, rectal, and pharyngeal sites with a single administration, as supported by the MMWR Recommendations and Reports 16

Gonorrhea Treatment Guidelines

Mandatory Follow-Up Requirements

• If nucleic acid amplification testing is positive at follow-up, confirm with culture, and all positive cultures should undergo phenotypic antimicrobial susceptibility testing, as recommended by the Centers for Disease Control and Prevention 17

Partner Management

• Consider expedited partner therapy with oral combination therapy (cefixime 400 mg plus azithromycin 1 g) if partners cannot be linked to timely evaluation, according to the Centers for Disease Control and Prevention 17

Gonorrhea and Chlamydia Treatment Guidelines

Special Populations

• The American College of Obstetricians and Gynecologists recommends using ceftriaxone 500 mg IM (single dose) + Azithromycin 1 g orally (single dose) in pregnant women, and advises against the use of doxycycline, quinolones, or tetracyclines in pregnancy 18

Men Who Have Sex with Men (MSM)

• The Centers for Disease Control and Prevention recommends that men who have sex with men (MSM) should not be treated with quinolones due to higher prevalence of resistant strains 19
• The Centers for Disease Control and Prevention also recommends that ceftriaxone is the only recommended treatment for MSM due to higher prevalence of resistant strains 20

Follow-Up Requirements

• The Centers for Disease Control and Prevention recommends that if symptoms persist after treatment, culture with antimicrobial susceptibility testing should be obtained 19
• The Centers for Disease Control and Prevention also recommends that if symptoms persist after treatment, culture with antimicrobial susceptibility testing should be obtained 20

Oral Treatment Options for Gonorrhea and Chlamydia

Special Populations

• The American Academy of Ophthalmology recommends using cefixime 400 mg orally PLUS azithromycin 1 g orally in pregnant patients if injection is refused, as doxycycline is contraindicated in pregnancy 21
• Doxycycline is contraindicated in pregnancy, nursing women, and children under 8 years, according to the American Academy of Ophthalmology 21

Gonorrhea Treatment Guidelines

Introduction to Gonorrhea Treatment

• The Centers for Disease Control and Prevention recommends screening for syphilis with serology at the time of gonorrhea diagnosis, and co-testing for HIV should also be performed given the facilitation of HIV transmission by gonorrhea 22

Alternative Regimens

• Oral cephalosporins are no longer first-line agents due to documented treatment failures in Europe, as reported by the Morbidity and Mortality Weekly Report 22

Critical Pitfalls to Avoid

• The Morbidity and Mortality Weekly Report advises against using fluoroquinolones (ciprofloxacin, ofloxacin) for gonorrhea treatment due to widespread resistance 22

Gonorrhea Treatment Guidelines

Introduction to Gonorrhea Treatment

• The Centers for Disease Control and Prevention recommends that patients with gonorrhea and their sexual partners from the preceding 60 days should be evaluated and treated for both gonorrhea and chlamydia, with the same dual therapy regimen 23

Partner Management

• The American College of Obstetricians and Gynecologists and other guideline societies support the concept of expedited partner therapy, which may be considered when partners cannot be linked to timely evaluation, using oral combination therapy (cefixime 400 mg plus azithromycin 1 g), but this approach is not recommended for men who have sex with men (MSM) due to the high risk of undiagnosed coexisting STDs or HIV 23

Ceftriaxone Dosage for Gonorrhea

Pharmacokinetics and Efficacy

• The 500 mg dose of ceftriaxone is particularly important for pharyngeal infections because extended-spectrum cephalosporins have marked variability in clearance and half-life within pharyngeal tissues, with nearly 90% being protein-bound in tonsillar tissue 24
• For suspected ceftriaxone treatment failure, recommended salvage regimens include gentamicin 240 mg IM PLUS azithromycin 2 g orally (single dose), or ertapenem 1 g IM for 3 days 24
• Higher doses of ceftriaxone (up to 3 g per dose with repeat dosing) are used in China without reported treatment failures, and a twice-daily dose of 2 g ceftriaxone would achieve sufficient free plasma concentrations for high-level resistant strains 24

Treatment of Uncomplicated Gonococcal Infection in Men

Primary Treatment Regimen

• The Centers for Disease Control and Prevention recommends ceftriaxone 500 mg intramuscularly as a single dose, plus doxycycline 100 mg orally twice daily for 7 days, for the treatment of uncomplicated gonococcal infection in men, with a high cure rate 25

Critical Pitfalls to Avoid

• The Centers for Disease Control and Prevention advises against using fluoroquinolones for gonorrhea treatment due to widespread resistance, despite their historical high cure rates 25
• The Centers for Disease Control and Prevention recommends against using azithromycin 1 g alone for gonorrhea, as it has only 93% efficacy and risks rapid resistance emergence 25

Follow-Up Requirements

• Patients treated with recommended ceftriaxone-based regimens do not need routine test-of-cure unless symptoms persist, according to the MMWR Recommendations and Reports 25
• The MMWR Recommendations and Reports suggests considering retesting all patients at 3 months due to high reinfection risk 25

Treatment for Gonorrhea Exposure

Rationale for Presumptive Treatment

• Gonorrhea transmission rates are high enough to warrant immediate treatment without waiting for test results, particularly because many infections are asymptomatic and patients may not return for follow-up, with co-infection with Chlamydia trachomatis occurring in 10-50% of gonorrhea cases, making dual therapy essential even for presumptive treatment 26, 27
• The Centers for Disease Control and Prevention (CDC) recommends that all sexual partners from the preceding 60 days should be evaluated and treated for both gonorrhea and chlamydia, regardless of symptoms or test results, due to the high transmission rates and potential for serious sequelae 26, 27

Transmissibility Context

• Gonorrhea is highly transmissible, with transmission occurring even from asymptomatic individuals, and many infections in women remain asymptomatic until complications like pelvic inflammatory disease develop, which can lead to tubal scarring, infertility, or ectopic pregnancy 26, 27

Gonorrhea Treatment Guidelines

Introduction to Gonorrhea Treatment

• The Centers for Disease Control and Prevention (CDC) recommends dual therapy for gonorrhea treatment, which includes a combination of two antimicrobials, such as ceftriaxone and azithromycin, to address chlamydial coinfection and potentially delay cephalosporin resistance 28

Treatment Regimens

• Cefixime should not be used as monotherapy without azithromycin or doxycycline, as this violates CDC dual therapy recommendations that mandate combination treatment to address chlamydial coinfection and potentially delay cephalosporin resistance 28
• The CDC recommends ceftriaxone 500mg IM plus azithromycin 1g orally as the first-line treatment regimen for gonorrhea, and cefixime is only an alternative regimen when ceftriaxone is unavailable 28

Follow-Up Requirements

• The CDC mandates test-of-cure at 1 week (7 days post-treatment) for all patients treated with cefixime-based regimens due to rising cefixime MICs and declining effectiveness 28
• Test-of-cure should ideally use culture (allows antimicrobial susceptibility testing) or NAAT if culture is unavailable, and if NAAT is positive, confirm with culture and perform phenotypic antimicrobial susceptibility testing 28

Partner Management

• The CDC recommends evaluating and treating all sexual partners from the preceding 60 days with the recommended dual therapy regimen: ceftriaxone 500mg IM plus azithromycin 1g orally 28
• Partners should receive expedited partner therapy with cefixime 400mg plus azithromycin 1g if they cannot be linked to timely evaluation 28

Cefixime-Based Regimens for Uncomplicated Gonorrhea

Efficacy of Cefixime

• The Centers for Disease Control and Prevention (CDC) recommends cefixime 400mg as an acceptable oral cephalosporin alternative when ceftriaxone is unavailable, with a 97.4% cure rate for uncomplicated urogenital and anorectal gonococcal infections 29

Preferred Treatment in Specific Situations

• Ceftriaxone 500mg IM is the superior initial choice for patients with recent foreign travel, due to the increased risk of resistant strains 29
• Ceftriaxone provides higher and more sustained bactericidal levels (98.9% cure rate) compared to cefixime (97.4% cure rate) 29

Management of Persistent Dysuria After Cefixime Treatment for Gonorrhea

Introduction to Gonorrhea Treatment

• The Centers for Disease Control and Prevention (CDC) recommends immediate re-evaluation with culture and antimicrobial susceptibility testing, followed by re-treatment with ceftriaxone 250 mg IM plus azithromycin 1 g orally, as cefixime monotherapy has suboptimal efficacy 30

Critical Problems with Current Management

• The CDC removed cefixime from first-line recommendations in 2012 due to documented treatment failures in Europe and rising resistance patterns, and it is only acceptable when ceftriaxone is unavailable 31

Immediate Next Steps

• Collect specimens from all potentially infected sites for culture with antimicrobial susceptibility testing, as persistent symptoms after treatment suggest either treatment failure or reinfection 30, 32
• Administer ceftriaxone 250 mg IM plus azithromycin 1 g orally as a single dose, preferably simultaneously and under direct observation, as this is the only CDC-recommended first-line regimen for gonorrhea treatment 30

Additional Considerations

• Evaluate and treat all sexual partners from the preceding 60 days with the recommended dual therapy regimen (ceftriaxone 250 mg IM plus azithromycin 1 g orally), as most post-treatment infections result from reinfection rather than treatment failure 30, 33
• Test for syphilis by serology and HIV at this visit, as gonorrhea facilitates HIV transmission and screening for syphilis should be performed when gonorrhea is detected 31, 33

Common Pitfalls to Avoid

• Fluoroquinolones should not be used for gonorrhea treatment due to widespread resistance 31
• Do not assume symptom resolution equals cure when suboptimal regimens were used—test-of-cure is mandatory 30

Evidence‑Based Recommendations for Gonorrhea Management (Cited)

Pharyngeal Infection Treatment Efficacy

• Spectinomycin provides only about a 52 % cure rate for pharyngeal gonorrhea, making it insufficient as a sole therapy for this site. (CDC MMWR Recommendations and Reports, 2002) 34

Contraindicated Monotherapy Regimens

• A single 1 g dose of azithromycin alone achieves roughly a 93 % cure rate for urogenital gonorrhea and is explicitly contraindicated because of its low efficacy and the rapid emergence of resistance. (CDC MMWR Recommendations and Reports, 2002) 34
• Fluoroquinolones such as ciprofloxacin or ofloxacin should never be used for gonorrhea treatment due to widespread antimicrobial resistance, despite historical cure rates of 99.8 %. (CDC MMWR Recommendations and Reports, 2002) 35

Partner and Sexual Activity Guidance

• Patients must refrain from sexual intercourse until the full treatment course is completed and both they and all treated partners are asymptomatic, to prevent ongoing transmission. (CDC MMWR Recommendations and Reports, 2002) 34

CDC Guidelines on Oral Regimens for Gonorrhea

Efficacy of Oral Cefixime

• In adults with pharyngeal gonorrhea, a single oral dose of cefixime 200 mg achieves a cure rate of 78.9 % (95 % CI 54.5 %–94 %)—considerably lower than injectable regimens, indicating limited reliability of cefixime for pharyngeal infection. The Centers for Disease Control and Prevention (CDC) notes this limitation in its recommendations 36.

Contraindicated Therapies

• The CDC advises against the use of fluoroquinolones (ciprofloxacin, ofloxacin) for gonorrhea treatment because of widespread antimicrobial resistance, even though these agents historically reported cure rates of ≈99.8 %. This shift reflects current resistance patterns that render fluoroquinolones ineffective. 37

Partner Management

• The CDC recommends that all sexual partners from the preceding 60 days be evaluated and treated with the dual‑therapy regimen of cefexime 400 mg orally plus azithromycin 1 g orally when timely clinical evaluation is not possible, to ensure both gonorrhea and chlamydia are addressed. 37

CDC Recommendations on Co‑infection and Antibiotic Resistance in Gonorrhea and Chlamydia

Co‑infection Prevalence

• In adult males with gonorrhea, co‑infection with Chlamydia trachomatis occurs in 20 %–50 % of cases, underscoring the need for simultaneous treatment of both pathogens. 38

Antibiotic Resistance Considerations

• Fluoroquinolones (ciprofloxacin, ofloxacin) are contraindicated for gonorrhea because of widespread resistance, despite earlier reports of ≈ 99.8 % cure rates. The CDC advises against their use. 38

Presumptive Treatment Guidelines

• Chlamydia treatment should not be omitted even when chlamydia testing is negative in a patient diagnosed with gonorrhea; presumptive dual therapy is recommended due to the high likelihood of co‑infection. This guidance comes from CDC recommendations. 38

Pregnancy Treatment Recommendations for Gonorrhea and Chlamydia Co‑Infection

Recommended Dual Therapy

• For pregnant individuals with confirmed gonorrhea–chlamydia co‑infection, administer a single intramuscular dose of ceftriaxone 500 mg together with a single oral dose of azithromycin 1 g. 39

Medications to Avoid in Pregnancy

• Doxycycline, quinolones, and all tetracyclines should not be used during pregnancy because of documented fetal safety concerns. 39

Acceptable Chlamydia Regimens in Pregnancy

• The only recommended options for treating chlamydia in pregnant individuals are:
  • Azithromycin 1 g given as a single oral dose, or
  • Amoxicillin 500 mg taken three times daily for 7 days. 39

Gonorrhea Management Guidelines (CDC)

Alternative Regimens and Efficacy

Pregnancy Considerations

Partner Management

Expedited Partner Therapy (EPT)

Sexual Activity Restrictions

Follow‑Up Testing

Reinfection

Special Populations

Site‑Specific Treatment

Contraindicated Medications

Evidence‑Based Recommendations for Uncomplicated Gonorrhea Management

First‑line Treatment Efficacy

• The CDC reports that a single 500 mg intramuscular dose of ceftriaxone cures 99.1 % of uncomplicated urogenital and anorectal gonorrhea infections, confirming its status as the preferred first‑line regimen. 43

Limitations of Alternative Cephalosporins and Other Agents

• Oral cefixime provides lower and less sustained bactericidal activity than ceftriaxone, contributing to reduced overall cure rates and necessitating a test‑of‑cure. 43
• Fluoroquinolones, although historically achieving 99.8 % cure rates, are now ineffective because of widespread resistance; the CDC therefore contraindicates their use for gonorrhea. 43
• Spectinomycin 2 g intramuscularly may be used for urogenital infection in patients with severe cephalosporin allergy, but it has poor efficacy for pharyngeal disease, limiting its applicability. 43

Site‑Specific Recommendations

• For gonococcal conjunctivitis, the CDC recommends a single 1 g intramuscular dose of ceftriaxone together with saline eye lavage. 44
• Disseminated gonococcal infection requires hospitalization; initial therapy is ceftriaxone 1 g intramuscularly or intravenously every 24 h until clinical improvement (24–48 h), after which oral therapy is continued to complete a total of one week of treatment. 44
• In cases of disseminated infection, clinicians should assess for endocarditis and meningitis as part of the evaluation. 44

Pregnancy Considerations

• The CDC advises that quinolones, tetracyclines, and doxycycline should never be used during pregnancy because of fetal safety concerns. 44
• When a severe cephalosporin allergy is present in pregnancy, the CDC permits the combination of spectinomycin 2 g intramuscularly plus azithromycin 1 g orally. 44

Ceftriaxone as First‑Line Therapy for Gonorrhea

Efficacy of Ceftriaxone

• Ceftriaxone achieves a 99 %–99.1 % cure rate for uncomplicated urogenital, anorectal, and cervical infections, making it the preferred first‑line agent. (Centers for Disease Control and Prevention, MMWR) 45
• For pharyngeal gonorrhea, ceftriaxone remains the only reliably effective option; oral cephalosporins such as cefixime cure only about 79 % of these infections. (CDC, MMWR) 45

Resistance Profile

• No ceftriaxone‑resistant Neisseria gonorrhoeae strains have been reported in the United States. (CDC, MMWR) 46
• Fluoroquinolones (ciprofloxacin, ofloxacin, levofloxacin) are now completely ineffective for gonorrhea because of widespread resistance, despite historic cure rates >99 %. (CDC, MMWR) 45

Dosing Recommendations

• Historically, 125 mg intramuscular ceftriaxone yielded ~99 % cure, but the current CDC recommendation is 500 mg IM as a single dose to preserve a therapeutic reserve against emerging resistance. (CDC, MMWR) 45

Administration Considerations

• Ceftriaxone is available only as an intramuscular injection; no oral formulation exists. (CDC, MMWR) 46
• A 1 % lidocaine diluent may be used by some clinicians to lessen injection discomfort. (CDC, MMWR) 46

Alternative Regimens When Ceftriaxone Is Unavailable

• Cefixime 400 mg orally as a single dose combined with azithromycin 1 g orally is an acceptable alternative, but a test‑of‑cure at one week is mandatory. (CDC, MMWR) 45
• Cefixime overall cures ≈97.4 % of infections but only ≈78.9 % of pharyngeal infections, which is significantly lower than ceftriaxone. (CDC, MMWR) 45

Contraindicated Agents

• Fluoroquinolones (ciprofloxacin, ofloxacin, levofloxacin) are absolutely contraindicated for gonorrhea treatment due to universal resistance. (CDC, MMWR) 45
• Quinolones are prohibited in persons ≤17 years of age. (CDC, MMWR) 46

Special Populations

• In men who have sex with men (MSM), ceftriaxone is the sole recommended therapy because of a higher prevalence of resistant strains; quinolones must never be used. (CDC, MMWR) 45

Azithromycin Resistance and Alternative Regimens for Gonorrhea in Penicillin‑Allergic Patients

Azithromycin Resistance and Efficacy of Alternative Therapies

• In North America, azithromycin resistance among Neisseria gonorrhoeae isolates ranges from 4 % to 7 %, whereas in certain East Asian regions resistance can be as high as 66 %. This geographic variability influences the reliability of azithromycin‑based regimens. 47
• The combination of gentamicin 240 mg intramuscularly plus azithromycin 2 g orally (single dose) achieved a 100 % microbiological cure rate for urogenital, rectal, and pharyngeal gonorrhea in clinical trials; however, its success is contingent on confirmed azithromycin susceptibility of the isolate. 47
• Azithromycin 2 g monotherapy should be avoided when azithromycin resistance is suspected or documented; in such cases, the gentamicin + azithromycin regimen should be used only after susceptibility testing confirms azithromycin activity. 47

Cephalosporin Side‑Chain Considerations in Penicillin‑Allergic Patients

• Cephalosporins possessing side chains that are dissimilar to the offending penicillin can be administered safely to patients with either immediate‑type or delayed‑type penicillin allergy. 48
• Cephalosporins that share side chains with cefalexin, cefaclor, or cefamandole should be avoided in patients with a suspected immediate‑type allergy to those specific agents, due to higher cross‑reactivity risk. 48
• Carbapenems are acceptable therapeutic options for patients with suspected immediate‑type cephalosporin allergy, providing a broader β‑lactam alternative when cephalosporins cannot be used. 48
• Aztreonam may be employed in individuals with cephalosporin allergy, except in patients who have a documented allergy to ceftazidime or cefiderocol, where cross‑reactivity remains a concern. 48

CDC (MMWR) Recommendations for Gonorrhoea Treatment (1998)

Alternative Regimens

• Spectinomycin 2 g intramuscularly is an alternative agent but achieves only about 52 % cure for pharyngeal gonorrhoea, making it unsuitable when pharyngeal exposure is possible. 49

Special Populations

Pregnancy

• Pregnant patients should receive ceftriaxone 500 mg intramuscularly plus azithromycin 1 g orally as a single dose. 49
• Quinolones, tetracyclines, and doxycycline are absolutely contraindicated in pregnancy because of fetal safety concerns. 49
• If a severe cephalosporin allergy is documented, the recommended alternative is spectinomycin 2 g intramuscularly plus azithromycin 1 g orally, although pharyngeal efficacy remains poor. 49

Site‑Specific Considerations

Pharyngeal Gonorrhoea

• Spectinomycin 2 g intramuscularly provides only ≈52 % cure for pharyngeal infection and should be avoided when pharyngeal exposure is suspected. 49

Gonococcal Conjunctivitis

• Treat with ceftriaxone 1 g intramuscularly as a single dose and perform a single saline lavage of the affected eye. 49

Disseminated Gonococcal Infection (DGI)

• Hospitalization is recommended for the initial management of DGI. 49
• Initial regimen: ceftriaxone 1 g intramuscularly or intravenously every 24 hours. 49
• For patients with a β‑lactam allergy, spectinomycin 2 g intramuscularly every 12 hours is an alternative. 49
• Clinicians should assess for endocarditis and meningitis and provide presumptive treatment for concurrent chlamydial infection. 49

Partner Management

• All sexual partners from the preceding 60 days must be evaluated and treated with the same ceftriaxone 500 mg IM + azithromycin 1 g PO dual therapy, regardless of symptoms or test results. 49
• If the patient’s most recent sexual contact occurred more than 60 days before symptom onset, treat the most recent partner. 49
• Patients must abstain from sexual intercourse until therapy is completed and both the patient and all partners are asymptomatic. 49

Follow‑Up and Test‑of‑Cure

• Retesting all patients at 3 months is advised because most post‑treatment positive tests represent reinfection rather than treatment failure. 49

Contraindicated Medications

• Fluoroquinolones (e.g., ciprofloxacin, levofloxacin) are absolutely contraindicated for gonorrhoea treatment due to widespread resistance, despite historical cure rates of ≈ 99.8 %. 49

Management of Gonococcal Conjunctivitis and Disseminated Gonococcal Infection

Gonococcal Conjunctivitis

• The CDC recommends a single intramuscular dose of ceftriaxone 1 g combined with a single saline lavage of the affected eye for treatment of gonococcal conjunctivitis. 50

Disseminated Gonococcal Infection (DGI)

Indications for Hospitalization

• Hospital admission is advised for initial therapy of DGI, particularly when patients present with purulent joint effusions, uncertain diagnosis, or anticipated poor adherence to outpatient treatment. 50

Initial Antimicrobial Regimen

• Begin therapy with ceftriaxone 1 g administered intramuscularly or intravenously once daily for 24–48 hours until clinical improvement, then transition to oral therapy to complete a total of 7 days of treatment. 50

Additional Evaluations

• Patients with DGI should be evaluated for possible endocarditis and meningitis as part of the comprehensive assessment. 50

Contraindicated Use of Quinolones in Adolescents

• The CDC advises that quinolone antibiotics (e.g., ciprofloxacin, levofloxacin, ofloxacin) are contraindicated in individuals aged ≤17 years based on animal‑study safety data. 51

CDC‑Guideline Recommendations for Gonorrhea Treatment (Cited Evidence)

Contraindicated Antimicrobials

• Fluoroquinolones (ciprofloxacin, ofloxacin, levofloxacin) are completely contraindicated for gonorrhea because of widespread resistance, even though historical cure rates exceeded 99% % 52.

Alternative Regimens When Ceftriaxone Is Unavailable

• Cefixime 400 mg orally as a single dose plus azithromycin 1 g orally as a single dose may be used only if ceftriaxone cannot be obtained 52.

Site‑Specific Management

• Gonococcal conjunctivitis: administer ceftriaxone 1 g intramuscularly as a single dose together with a single saline eye lavage 53.
• Disseminated gonococcal infection: hospitalize the patient and give ceftriaxone 1 g intramuscularly or intravenously every 24 hours for 24–48 hours until clinical improvement, then switch to oral therapy to complete a total of 1 week of treatment 53.

CDC Guidelines for Gonorrhea Treatment in Men

Alternative Regimens When Ceftriaxone Is Unavailable

• The CDC states that a single oral dose of cefixime 400 mg combined with azithromycin 1 g is acceptable only when ceftriaxone cannot be obtained; this regimen achieves a 97.4 % cure rate for urogenital infections (compared with 99.1 % for ceftriaxone) and requires a mandatory test‑of‑cure at one week. 54
• Cefixime provides lower and less sustained bactericidal concentrations than ceftriaxone, which explains its reduced efficacy. 54

Contraindicated Medications

• Fluoroquinolones (ciprofloxacin, ofloxacin, levofloxacin) are completely contraindicated for gonorrhea treatment because of widespread resistance, despite historic cure rates >99 %. [54][55]
• Azithromycin 1 g used as monotherapy should never be employed; it yields only ~93 % efficacy and promotes rapid resistance development. 55

Management of Severe Cephalosporin or Beta‑Lactam Allergy

• For patients with a severe cephalosporin allergy, the CDC recommends a single oral dose of azithromycin 2 g together with a mandatory test‑of‑cure at one week; this approach has lower efficacy (≈93 %) and is associated with notable gastrointestinal side effects. 55

Partner Management

• All sexual partners within the preceding 60 days should be evaluated and treated with the same dual‑therapy regimen (ceftriaxone 500 mg IM + doxycycline or azithromycin), irrespective of symptoms or test results. 56
• If the most recent sexual contact occurred more than 60 days before symptom onset, the most recent partner should still receive treatment. 56
• Patients must abstain from sexual activity until therapy is completed and both the patient and all partners are asymptomatic. 56

Follow‑Up Testing

• Routine test‑of‑cure is not required for patients who receive the recommended ceftriaxone‑based regimen unless symptoms persist after treatment. 56
• When symptoms persist, cultures with antimicrobial susceptibility testing should be obtained from all potentially infected sites; persistent positive results usually represent reinfection rather than true treatment failure. 56
• All patients should be retested at three months because reinfection rates are high (approximately 20–30 %). 56

Site‑Specific Considerations – Pharyngeal Gonorrhea

• Pharyngeal infections are markedly harder to eradicate; ceftriaxone 500 mg IM remains the only reliably effective therapy, whereas oral cephalosporins achieve only about 78.9 % cure of pharyngeal infections. 54
• Spectinomycin 2 g IM cures only ~52 % of pharyngeal infections and should be avoided when pharyngeal exposure is possible. 56

General Principle on Oral Cephalosporins

• The CDC emphasizes that oral cephalosporins should not be considered equivalent to ceftriaxone because they have inferior efficacy, especially for pharyngeal disease. 54

Management of Asymptomatic Sexual Partners of Gonorrhea Patients

Immediate Empiric Treatment

• The CDC recommends that all asymptomatic sexual partners of a patient with confirmed gonorrhea receive the same dual‑therapy regimen as the index case immediately, without awaiting test results. [57][58]

Timing‑Based Partner Treatment Criteria

• Symptomatic index patient: Treat every partner whose last sexual contact occurred ≤ 30 days before symptom onset. [59][57]58
• Asymptomatic index patient: Treat every partner whose last sexual contact occurred ≤ 60 days before the diagnosis. [59][57]58
• Contacts outside the above windows: Treat the most recent partner regardless of how long ago the encounter occurred. [57][58]

Treatment Regimens for Specific Populations

Pregnant Partners

• Use ceftriaxone 500 mg intramuscularly plus azithromycin 1 g orally as a single dose. [59][58]
• Do not use quinolones, tetracyclines, or doxycycline in pregnancy because of fetal safety concerns. [59][58]

Partners with Severe Cephalosporin Allergy

• Administer spectinomycin 2 g intramuscularly plus azithromycin 1 g orally as a single dose. [59][58]

Sexual Activity Restrictions and Follow‑Up

• Partners must abstain from sexual intercourse until (a) therapy is completed for both the index patient and all partners and (b) all individuals are asymptomatic. [59][57]58

Additional Screening

• At the time of gonorrhea diagnosis, screen partners for syphilis by serology. 58

Immediate Notification and Treatment

• Upon notification, treat partners without delay, even before their own test results are available. [57][58]

Alternative Gonorrhea Treatments When Ceftriaxone Is Unavailable

Pharyngeal Infection Efficacy

• The CDC notes that oral cefixime 400 mg plus azithromycin 1 g cures only 78.9–89 % of pharyngeal gonorrhea, markedly lower than the ≈99 % cure rate with ceftriaxone; this reduced efficacy is important because the pharynx serves as a reservoir for antimicrobial‑resistance development and infections can remain asymptomatic for up to 16 weeks. 60

• A 2024 Lancet Infectious Diseases study that was halted early reported that only 2 of 10 participants (20 %) with pharyngeal gonorrhea treated with gentamicin 240 mg IM plus azithromycin 2 g orally achieved microbiological cure, indicating very poor pharyngeal activity of this regimen. Evidence strength: low (early‑terminated trial). 60

• CDC‑backed MMWR data show that spectinomycin 2 g IM cures only about 52 % of pharyngeal infections, making it unsuitable when pharyngeal exposure is possible or suspected. Evidence strength: moderate (surveillance‑based recommendation). 61

Cure Rates for Urogenital and Anorectal Sites

• According to CDC‑endorsed MMWR recommendations, spectinomycin 2 g IM achieves a 98.2 % cure rate for urogenital and anorectal gonorrhea, providing an effective option for these sites when ceftriaxone cannot be used. Evidence strength: moderate. 61

Alternative Injectable Cephalosporins (When Ceftriaxone Unavailable)

• CDC’s 2006 MMWR report lists ceftizoxime 500 mg IM, cefoxitin 2 g IM with probenecid 1 g orally, and cefotaxime 500 mg IM as injectable cephalosporins that are effective against gonorrhea but offer no advantage over ceftriaxone in terms of efficacy or resistance suppression. Evidence strength: moderate (expert consensus). 61

Salvage Regimens for Confirmed Treatment Failure

• The Lancet Infectious Diseases (2024) recommends ertapenem 1 g IM daily for 3 days as a salvage therapy for gonorrhea cases in which first‑line or alternative regimens have failed. Evidence strength: moderate (clinical trial data). 60